UTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance SALT LAKE CITY, UT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via – With Revenues 4% lower and Net Income and Earnings Per Share 1% higher than in 2022, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved financial results for the full year of 2023 consistent with management’s beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in ...
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2023 SALT LAKE CITY, UT, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via – Utah Medical Products, Inc. [Nasdaq: UTMD], despite a difficult third calendar quarter (3Q), achieved financial results for nine months (9M) 2023 consistent with those anticipated in its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, e...
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2023 SALT LAKE CITY, UT, July 25, 2023 (GLOBE NEWSWIRE) -- via – Utah Medical Products, Inc. [Nasdaq: UTMD] achieved second calendar quarter (2Q) and first half (1H) 2023 financial results consistent with those anticipated in its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amount...
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2023 SALT LAKE CITY, UT, April 25, 2023 (GLOBE NEWSWIRE) -- via - In the first calendar quarter (1Q) of 2023, Utah Medical Products, Inc. (Nasdaq: UTMD) attained financial results consistent with achieving its goals previously announced for calendar year 2023. Summary of results. The following is a summary comparison of 1Q 2023 with 1Q 2022 income statement measures: Revenues (Sales):+ 1.6%Gross Profit (GP):+ 4.1%Operating Income (OI):( 1.9%)Net Income (NI):+19.2%Earnings Per Share (EPS):+20....
UTMD Reports Audited Year 2022 and Fourth Quarter Financial Performance SALT LAKE CITY, UT, Jan. 31, 2023 (GLOBE NEWSWIRE) -- via – Utah Medical Products, Inc. (Nasdaq: UTMD) finished the calendar year with a solid fourth quarter (4Q) performance, which allowed financial results for the year 2022 exceeding management’s beginning of year projections, despite many challenges. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this repo...
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2022 SALT LAKE CITY, UT, Oct. 25, 2022 (GLOBE NEWSWIRE) -- via - In the third calendar quarter (3Q) of 2022, despite significant cost inflation, supply chain disruption, litigation expenses and negative impact of a stronger U.S. Dollar on foreign currency sales, Utah Medical Products, Inc. (Nasdaq: UTMD) continued to achieve financial results which were better than those anticipated in its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; ...
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2022 SALT LAKE CITY, UT , July 26, 2022 (GLOBE NEWSWIRE) -- via --UTMD achieved second calendar quarter (2Q) and first half (1H) 2022 financial results better than those anticipated in its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. Because of the relat...
A director at Utah Medical Products Inc sold 2,000 shares at 85.198USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2022 SALT LAKE CITY, UT, April 26, 2022 (GLOBE NEWSWIRE) -- via – In the first calendar quarter (1Q) of 2022, Utah Medical Products, Inc. (Nasdaq: UTMD) attained financial results consistent with achieving its goals for calendar year 2022. Summary of results.The following is a summary comparison of 1Q 2022 with 1Q 2021 income statement measures: Revenues (Sales): +12.4%Gross Profit (GP): + 8.4%Operating Income (OI): +16.3%Net Income (NI): +16.9%Earnings Per Share (EPS): +16.6% Prof...
UTMD Reports Audited Year 2021 and Fourth Quarter Financial Performance Salt Lake City, Utah, Feb. 01, 2022 (GLOBE NEWSWIRE) -- via -- The fourth calendar quarter (4Q) of 2021 financial results demonstrate Utah Medical Products, Inc.’s (Nasdaq: UTMD’s) continuing performance improvement despite many challenges related to the corona virus pandemic including on-again/off-again restrictions on so-called nonessential medical procedures, supply chain disruption, high inflation on raw materials, freight and labor costs as well as a continued shortage of labor and higher employee turnover. Beca...
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2021 Salt Lake City, Utah, Oct. 26, 2021 (GLOBE NEWSWIRE) -- via -- The third calendar quarter (3Q) of 2021 financial results continued to demonstrate Utah Medical Products, Inc.’s (Nasdaq: UTMD’s) recovery after a time when there were restrictions on so-called nonessential medical procedures during the COVID-19 pandemic. Because of the unusual dip in 2020 demand for its devices, UTMD management continues to report quarterly income statement results compared to the same periods not only in 2021 compared to 2020...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2021 Salt Lake City, Utah, July 22, 2021 (GLOBE NEWSWIRE) -- via -- The second calendar quarter (2Q) of 2021 financial results were dramatically different from 2Q 2020 because 2Q 2020 results were the low point of Utah Medical Products, Inc.’s (Nasdaq: UTMD) performance during the COVID-19 pandemic, during a time when there were restrictions on so-called nonessential medical procedures. Therefore, UTMD management reports quarterly income statement results compared to the same periods not only in 2021 compared t...
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2021 Salt Lake City, Utah, April 22, 2021 (GLOBE NEWSWIRE) -- via -- Because of the aberration in results which began in March 2020 due to the impact of restrictions on “nonessential” medical procedures, Utah Medical Products, Inc. (Nasdaq: UTMD) will report 2021 quarterly income statement results compared to the same periods in both 2020 and 2019. Please see the income statement on the last page. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or...
Utah Medical Products, Inc. Terminates its Shareholder Rights Agreement Salt Lake City, UT , March 01, 2021 (GLOBE NEWSWIRE) -- -- Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors, acting by unanimous written consent, terminated the Company’s Shareholder Rights Agreement, sometimes referred to as a “poison pill.” The Rights Agreement with a ten year life was originally approved by a vote of all shareholders at the 1994 Annual Meeting, and then was extended in 2004 and again in 2014 by the board without a shareholder vote. The board elected to terminate th...
UTMD Reports Audited Year 2020 and Fourth Quarter Financial Performance Salt Lake City, Utah, Jan. 28, 2021 (GLOBE NEWSWIRE) -- via -- Utah Medical Products, Inc. (Nasdaq: UTMD) reports financial results for the fourth calendar quarter (4Q) which confirms a trend of recovery from the “COVID-19 depression” in 2Q 2020 caused by government policies restricting medical procedures deemed “nonessential” such as tubal ligation and loop excision of the transformation zone. In this report, UTMD presents 2020 successive quarterly comparisons. In summary, 4Q 2020 was UTMD’s best revenue quarter o...
UTMD Reports Financial Performance for Third Quarter and Nine Months of Year 2020 Salt Lake City, UT, Oct. 27, 2020 (GLOBE NEWSWIRE) -- --For the third calendar quarter (3Q) and first nine months (9M) of 2020, Utah Medical Products, Inc. (Nasdaq: UTMD) reports financial results described by CEO Kevin Cornwell as follows, “As stockholders know, the desire to preserve capacity for treating patients with COVID-19 led to suspending many hospital medical procedures. As a result, UTMD began to experience lower demand for its specialty medical devices in March during 1Q 2020. As the largest ...
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2020 Salt Lake City, Utah, July 28, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- As many of the gynecology devices provided by Utah Medical Products, Inc. (Nasdaq: UTMD) are used in “nonessential” or “elective” procedures, as medical procedures have been reclassified during the COVID-19 pandemic, the Company’s financial performance in the second calendar quarter (2Q) and first half (1H) of 2020 reflects a substantial negative change relative to the same periods in 2019. According to CEO Kevin Corn...
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2020 Salt Lake City, Utah, April 23, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- In the first calendar quarter (1Q) of 2020, Utah Medical Products, Inc. (Nasdaq: UTMD) attained results consistent with 1Q 2019, despite realizing a negative impact from the public response to the corona virus (COVID-19). Summary of results.The following is a summary comparison of 1Q 2020 with 1Q 2019 income statement measures: Revenues (Sales):+ 2%Gross Profit (GP):+ 1%Operating Income (OI): ( 6%)Net Income (NI): -Earnings Per...
UTMD Postpones its 2020 Annual Stockholders’ Meeting for Three Months Salt Lake City, UT, March 23, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- As stockholders of Utah Medical Products, Inc. (Nasdaq: UTMD) appreciate, as a result of the recent rapid spread of the COVID-19 (corona virus), the warnings/ advice/ mandates of government authorities and infection disease experts to avoid travel and in-person meetings is in direct contravention to the legal requirement for publicly-owned companies to hold annual meetings in which stockholders can engage management. UTMD’s scheduled time to hold...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.